

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF ART UNIT: 1625
GASPARINI, FABRIZIO ET AL. EXAMINER: REESE, HEIDI L
INTERNATIONAL APPLICATION NO: PCT/EP2004/010743
FILED: SEPTEMBER 24, 2004
U.S. APPLICATION NO: 10/573162
35 USC §371 DATE: MAY 5, 2006
FOR: PYRIDYLACETYLENES FOR USE AS RADIOTRACERS AND
IMAGING AGENTS

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Novartis Pharmaceuticals Corporation
One Health Plaza, Bldg. 101
East Hanover, NJ 07936
(862) 778-9587

Date: 2/7/11

Respectfully submitted,



Daniel Woods
Attorney for Applicant
Reg. No. 59,864